You are here: Industry Insights > First patient

News List

I-Mab Biopharma Announces Dosing of First Patient in a Pivotal Study of TJ202/MOR202 in Multiple Myeloma in Mainland China prnasia
January 05, 2020
I-Mab initiated two registrational trials with TJ202/MOR202 in relapsed or refractory MM in Taiwan, China in early 2019 and expanded these trials into mainland China in late 2019, after receiving IND clearance from the National Medical Products Administra
First Patient Enrolled in Primary Sclerosing Cholangitis Trial americanpharmaceuticalreview
August 13, 2019
Immunic announced enrollment of the first patient in an investigator-sponsored proof-of-concept clinical trial of IMU-838 for the treatment of patients with primary sclerosing cholangitis (PSC). IMU-838 is an orally available ...
Biohaven Enrolls First Patient in Verdiperstat Phase 3 Clinical Trial americanpharmaceuticalreview
August 01, 2019
Biohaven announced it has enrolled the first patient in a Phase 3 clinical trial to evaluate the efficacy and safety of verdiperstat in subjects with Multiple System Atrophy (MSA).
First Patient Dosed with DNA-based, Neoantigen-Targeting Personalized Vaccine from Geneos americanpharmaceuticalreview
July 12, 2019
Geneos Therapeutics, a clinical-stage biotech company, a spin-out of Inovio Pharmaceuticals, announced the first cancer patient was dosed using the company's GT-EPIC Neoantigen-Targeting Personalized Vaccine Technology.
I-Mab Announces Dosing of First Patient in a Phase I Clinical Trial of TJC4 americanpharmaceuticalreview
June 26, 2019
I-Mab Biopharma announced the first patient has been dosed in a Phase I clinical trial of TJC4. The study is known as TJ011133 (NCT Number: NCT03934814).
Tolero Announces First Patient Dosed with Investigational Agent TP-0903 americanpharmaceuticalreview
June 13, 2019
Tolero Pharmaceuticals announced the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0903, an AXL receptor tyrosine kinase (RTK) inhibitor, in patients with previously treated chronic lymphocytic leukemia (CLL) an
Rocket Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of RP-L102 in the U.S. firstwordpharma
March 13, 2019
Rocket Pharmaceuticals, Inc.(NASDAQ:RCKT) ("Rocket"), a leading U.S.-based multi-platform gene therapy company, today announces that the first patient has been dosed in the open-label, Phase 1 clinical trial of RP-L102, the Company's lentiviral vector (LV